The emerging global threat from COVID-19 demanded immediate action. With cases rising rapidly, we set up a specialist team to use our AI-drug discovery platform to search for existing drugs — already proven safe — that could be repurposed to treat the virus.
Together by building bespoke drug repurposing workflow customisations, we used our Knowledge Graph and AI tools to search for approved drugs that could treat COVID-19, focusing on those that might block the viral infection process. We identified baricitinib — a drug owned by Eli Lilly and approved to treat rheumatoid arthritis — as the strongest treatment candidate.
Our hypothesis sparked global clinical trials and the drug we identified is now approved by the FDA to treat COVID-19.
Our hypothesis prompted global clinical trials. Following unprecedented global scientific collaboration, baricitinib now is authorised to treat hospitalised COVID-19 patients in the US, Japan and India.